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• Ovarian cancer screening using CA125 cut-off has shown no mortality beneﬁt.
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UKCTOCSEvidence of amortality beneﬁt continues to elude ovarian cancer (OC) screening. Data from theUSProstate, Lung,
Colorectal and Ovarian (PLCO) Cancer Screening Trial which used a screening strategy incorporating CA125 cut-
off and transvaginal ultrasound has not shown mortality beneﬁt. The United Kingdom Collaborative Trial of
Ovarian Cancer Screening (UKCTOCS) is using the Risk of Ovarian Cancer (ROC) time series algorithm to interpret
CA125,which has shown an encouraging sensitivity and speciﬁcity however themortality datawill only be avail-
able in 2015. The article explores the impact of growing insights into disease aetiology and evolution and bio-
marker discovery on future screening strategies. A better understanding of the target lesion, improved design
of biomarker discovery studies, a focus on detecting low volume disease using cancer speciﬁc markers, novel
biospecimens such as cervical cytology and targeted imaging and use of time series algorithms for interpreting
markers proﬁle suggests that a new era in screening is underway.
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There is growing evidence that screening can impact on cancer spe-
ciﬁc mortality. Many countries have national screening programmes for
breast, bowel and cervical cancers with the latter associatedwith signif-
icant (50–90%) reduction in disease speciﬁc mortality [1]. Key to theved.
Table 1
Summary of the key ﬁndings of the four major ovarian cancer screening trials.
Ovarian cancer screening trials in the general population
University of Kentucky Study [8,9] Japanese Shizuoka Cohort
Study of Ovarian Cancer
Screening [12]
Prostate, Lung, Colorectal
and Ovarian (PLCO) Cancer
Screening Trial [3,4]
United Kingdom Collaborative
Trial of Ovarian Cancer Screening
(UKCTOCS) [13,15,16]
Study design Single arm prospective study RCT with 1 screening strategy
in study group
RCT with 1 screening strategy
in study group
RCT with 2 screening strategies in
the study group
Cohort 25,327 41,688 30,630 98,305
Screening strategy Ultrasound Physical exam, ultrasound
and CA125
Ultrasound and CA125 Two screening arms (ultrasound,
USS) and CA125 followed by
ultrasound (multimodal, MMS)
Interpretation of CA125 CA125 using a 35 kU/l cut-off CA125 using a 35 kU/l cut-off CA125 interpreted using the Risk
of Ovarian Cancer (ROC) algorithm
Key screening ﬁndings Encouraging sensitivity (81%)
for primary OC/FT cancer; 76.3%
for primary invasive OC/FT cancer
Encouraging sensitivity (77.1%)
for primary OC/FT cancer
Lower sensitivity (69.5%) for
primary OC/FT cancer; 68.2%
for primary invasive OC/FT cancer
when compared to the other trials
(only 28% were Stage I/II)
Encouraging sensitivity (89.4%
MMS/84.9% USS) for primary OC/FT
cancer; 84.9% MMS/75.0% USS for
primary invasive OC/FT cancer
(47% MMS/50% USS were Stage I/II).
Superior sensitivity (88.6% vs 65.8%)
and PPV (21.7% vs 5.8%) of MMS
compared to the USS arm for detection
of primary invasive epithelial OC/FT
cancers during incidence screening,
with 40.3% in the MMS and 51.5% in
the USS arm detected at early stage.
Key mortality/surrogates
of mortality ﬁndings
Longer 5-year survival in the
screened arm (74.8%) compared to
unscreened women from the same
institution treated by the same
surgical and chemotherapeutic
protocols (53.7%) (p b 0.001).
Stage shift: more Stage I ovarian
cancers in the screened group (63%)
compared to the control (38%)
No mortality beneﬁt: 118 ovarian
cancer deaths in the screened arm,
100 in the control arm
Mortality data awaited in 2014/2015
Current status Completed Mortality data to be reported Completed Mortality data to be reported in 2015
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history of the cancer and the existence of a precursor lesion. Evidence
of a mortality beneﬁt continues to elude ovarian cancer (OC) screening
and the US Preventive Services Task Force (USPSTF) has recently
reconﬁrmed their previous recommendation that it should not be un-
dertaken in the general population [2]. However a number of novel in-
sights in the last few years into disease aetiology, evolution and
biomarker discovery suggest that a new era in screening is underway.
The current article reviews the evidence from recently reported OC
screening trials and explores the impact of the growing understanding
of OC on future screening strategies.
Current status
A number of large prospective trials have reported in the last few
years (Table 1). The ovarian arm of the Prostate, Lung, Colorectal and
Ovarian (PLCO) Cancer Screening Trial was a randomised controlled
trial (RCT) of 68,616 women aged 55 to 74 of whom 30,630 underwent
screening between 1993 and 2007. The women were screened using
serum CA125 using a cut-off of ≥35 kU/l and transvaginal ultrasound
(TVS) for 4 years followed by CA125 alone for a further 2 years. Positive
results were evaluated and managed by the participants' physicians
with no prescribed study protocol [3]. At a median follow-up of
12.4 years (25th–75th centile 10.9–13.0), 118 and 100 deaths were re-
ported in the screening and control arm, respectively, with a mortality
rate ratio of 1.18 (95%CI 0.91–1.54). Moreover, there was a high (15%)
serious complication rate in women undergoing surgery for false posi-
tive ﬁndings [4]. Limitations of the trial include the use of a single
threshold rule to interpret CA125 as women were returned to annual
screening if CA125 was within normal limits (b35 U/ml), lack of a cen-
tral protocol driven management and the lengthy follow-up after
screening was completed due to a signiﬁcant healthy volunteer effect
in trial participants [5]. The long follow-up resulted in 40.6% of
women with OC in the study arm being diagnosed after the end of
screening [6]. It was these ﬁndings that led to the USPSTF reconﬁrming
that OC screening should not be undertaken in the low risk population.Despite these recommendations, a recent survey of US physicians indi-
cated that one in three physicians believed that OC screening was effec-
tive and were likely to offer it to the women [7].
More encouraging data regarding survival was obtained from the
Kentucky Screening Study, a single arm annual ultrasound screening
study of 25,327 women [8]. At a mean follow-up of 5.8 years, the
5-year survival rates in women diagnosed with primary invasive epithe-
lial OC (screen positives and interval cancers) in the screening study
were signiﬁcantly higher (74.8% +/− 6.6%) compared towomen treated
at the same institution during the same period who were not study par-
ticipants (53.7% +/− 2.3%) [9]. However these rates are not comparable
due to the ‘lead time effect’ of screening. In addition, as the Kentucky
Study was not an RCT, it is likely that there was a signiﬁcant ‘healthy
volunteer effect’ that contributed to higher survival in those who partic-
ipated [10]. This is supported bydata fromboth PLCOTrial and theUnited
Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS),
where in the control arm (no intervention), the all-cause mortality was
less than half that expected due to a ‘healthy volunteer effect’ [5,11].
The Japanese Shizuoka Cohort Study of Ovarian Cancer Screening
was an RCT of 82,487 low-risk postmenopausal women who were
screened using an annual ultrasound and CA125 using a cut-off. The
trial showed encouraging sensitivity (77.1%) and speciﬁcity (99.9%)
with the screened women more likely to be detected at an early stage
(63%) compared to the control arm (38%) [12]. The mortality effect
has however not been reported as yet.
The largest screening trial to date is UKCTOCS, an RCT of 202,638
women from the general population randomised in 2001–2005 to no
intervention (control) or annual screening using either transvaginal ul-
trasound (USS) or serum CA125 interpreted by a ‘Risk of Ovarian Can-
cer’ algorithm (ROCA) with transvaginal ultrasound as a second line
test (multimodal screening, MMS). ROCA is a Bayesian algorithm [13]
that compares the CA125 proﬁle of cases to that of healthy women
and incorporates age-speciﬁc incidence of OC in calculating risk. The
closer the individual's proﬁle is to the pattern of diseased women, the
higher the estimated risk. During prevalence screening, both MMS and
USS strategies had encouraging sensitivity for primary invasive
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signiﬁcantly higher in the MMS group (35.1% versus 2.8% in USS)
resulting in lower rates of repeat testing and surgery [14]. This in part
reﬂects the high prevalence of benign adnexal abnormalities and the
more frequent detection of borderline tumours in theUSS group. During
incidence screening, although the speciﬁcity remained high, the multi-
modal strategy had superior sensitivity (88.6% vs 65.8%) and PPV
(21.7% vs 5.8%) compared to the USS arm for detection of primary inva-
sive epithelial ovarian and fallopian tube cancers [15,16]. The perfor-
mance of the ultrasound strategy was similar between PLCO and
UKCTOCS. The proportion of cases detected in Stage I/II was 47.1% at
prevalence and 40.3% at incidence in the MMS arm and 50% at preva-
lence and 51.5% at incidence in the USS arm. Screening in the trial was
completed in December 2011 and results of the mortality impact are
awaited in 2014–5.
More recently, a single-arm US prospective study of 4051 low risk
postmenopausal women aged N50 screened using ROCA has reported
detecting 4womenwith invasive OC of 10whounderwent surgery dur-
ing 11 years of screening. All screen-detected cancers were ‘early-stage
high-grade’ invasive epithelial OC and no interval cancers were report-
ed. This study provides independent validation of the UK ﬁndings of
high speciﬁcity (99.9%) and PPV (40%) of ROCA [17].
In women at increased risk due to a family history or conﬁrmedmu-
tation in high penetrance genes such as BRCA1/2, annual screeningwith
CA125 using a cut-off and TVS does not detect early stage cancers
[18,19]. This was conﬁrmed again by the recent report from Phase I of
the UK Familial Ovarian Cancer Screening Study (UKFOCSS). Between
2002 and 2008, 3563 women underwent annual screening with
serum CA125 and TVS. Whilst the sensitivity for detection of incident
OC/FT cancer within a year of the last annual screen was high (81.3%–
87.5% depending on whether occult cancers were classiﬁed as interval
cancers or true positives), only 30.8% of screen-detected OC/FTCs were
Stage I/II. Therewas a suggestion that strict adherence to annual screen-
ing had an impact as Stage ≥IIIC disease was more likely (85.7% versus
26.1%; p = 0.009) in those who had not had screening in the year be-
fore diagnosis compared to those who had screening [20]. The prelimi-
nary ﬁndings led to UKFOCSS Phase II where annual CA125 screening
was replaced by 4-monthly serum CA125 interpreted using the ROCA.
The preliminary results presented at the American Society of Clinical
Oncology meeting in 2013 suggest that this strategy had high (67–
100%) sensitivity for ovarian and tubal cancers, with no interval cancers
reported. In Phase II, 42% of incident screen-detected OC/FT cancers
were Stage I/II. However, 92% of incident screen-detected cancers
were completely cytoreduced compared to 62% on Phase I (p = 0.16).
Whilst the results were encouraging, it is important to note that screen-
ing at present cannot be considered a safe alternative to risk-reducing
surgery [21]. A similar strategy was also assessed prospectively in the
US screening trials in high-risk women undertaken under the auspices
of the Cancer Genetics Network [22] and Gynaecology Oncology
Group [23]. Screening is complete in all of these trials with results ex-
pected later this year.
Lessons from past biomarker failures
In the past decade, major efforts have been made to improve on the
performance of CA125 in differential diagnosis of pelvic masses and
screening. Despite a plethora of biomarkers being investigated, CA125 re-
mains the single-best biomarker forOC. In a studyof 35 of themost prom-
ising OC biomarkers, using samples from the PLCO Trial bank taken from
118womenwithin 6 months prior to OC diagnosis and 951 age-matched
controls, CA125 had the best sensitivity at 86%, with Human Epididymis
Protein 4 (HE4) the second best performing marker with a sensitivity of
73% [24]. HE4 has so far not been approved for use in screening, although
a commercial test, Risk of Ovarian Malignancy Algorithm, ROMA, that
combines HE4, CA125II and menopausal status is in use for pre-
operative triaging of women [25]. The performance of all markers waspoorer in the PLCO study when assayed in samples taken more
than 6 months from diagnosis [26]. Further studies found no improve-
ment in performance over CA125 alone of a comprehensive panel that
included 28 of the most promising OC biomarkers or smaller panels of
6 to 8 biomarkers [26] in samples within 12 months of diagnosis.
This failure to ﬁnd useful biomarkers, despite major investment and
research has led to explorations of the possible causes [27,28]. A lack of
rigour in all three phases of biomarker discovery andvalidation has been
identiﬁed; preanalytical—case selection, matching of controls and sam-
ple processing and storage, analytical—detection limit and precision of
assays, and post-analytical—overﬁtting and data interpretation to yield
‘the next promising’ marker. There is a growing consensus that bio-
markers discovered in clinical sample sets collected at diagnosis from
symptomatic patients and controls in hospital settings may not be rep-
resentative of the screening population. As a result, a key recommenda-
tion that has emerged is the use of the PRoBE (prospective-specimen
collection, with retrospective-blinded evaluation) design for biomarker
discovery and validation [29]. This involves blinded case control studies
nestedwithin a prospective cohort that represents the target population
where biologic specimens and clinical data have been collected prior to
ascertainment of outcome such as OC diagnosis on follow-up.
Increasingly samples predating diagnosis (preclinical/prediagnostic)
are available from the biobanks built during the course of large cohort
studies and screening trials. In a nested case control study using preclin-
ical samples from the Carotene and Retinol Efﬁcacy Trial (CARET)
biobank, a panel of CA125, HE4, and mesothelin was found to provide
a signal three years before OC diagnosis [30] whilst a nested case
control study from UKCTOCS reported elevation of Putative Platelet
Factor 4 (PF4) and connective tissue-activating peptide III (CTAPIII) 11
and 15 months respectively before OC diagnosis and before the rise in
CA125 [31].
Deﬁning the target lesion—new insights into carcinogenesis
Malignant ovarian neoplasm, coded C56 by the International Classi-
ﬁcation of Diseases and Related Health Problems 10th revision code
(ICD-10), is a heterogeneous group of ovarian tumours that include pri-
mary invasive epithelial, borderline epithelial (LMP) and non-epithelial
OC. Over the years, signiﬁcant confusion has existed as towhich of these
subtypes of OC constitute a valid target for ovarian cancer screening.
More recently there seems to be growing consensus that it should be re-
stricted to primary invasive epithelial OC as it is the main cause of dis-
ease mortality. Increasing evidence that primary invasive epithelial
ovarian, fallopian tube (ICD-10 C57.0) and primary peritoneal (ICD-10
C48) carcinomas areMüllerian in nature has led to debate as towhether
they represent a single disease entity ‘pelvic serous cancer’ [32,33]. This
would suggest the widening of the spectrum of targeted cancers in OC
screening. In UKCTOCS, the strategy focused on detecting primary
tubal cancers in addition to malignant ovarian neoplasms [14], whilst
in the PLCO Trial primary peritoneal cancers were also included in the
primary outcome measure [4].
Based on distinctive morphologic and molecular genetic features,
‘invasive epithelial’ OCs can broadly be classiﬁed into two groups [34].
Type I are slow growing cancers with better prognosis such as low-
grade serous, low-grade endometrioid, clear cell, mucinous and transi-
tional (Brenner) carcinomas. These tumours generally behave in an in-
dolent fashion, are conﬁned to the ovary at presentation and are
relatively genetically stable. They lack mutations of TP53 with each his-
tologic type exhibiting a distinctive molecular genetic proﬁle. They
share lineage with the corresponding benign cystic neoplasm, often
through an intermediate (borderline tumour) step, supporting themor-
phologic continuum of tumour progression. Endometrioid and clear cell
tumours are associated with endometriosis [35] and many consider the
endometrium to be the source of these ovarian neoplasms [34]. Prelim-
inary data suggest that mucinous and transitional (Brenner) tumours
arise from transitional-type epithelial nests at the tubal–mesothelial
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to have higher sensitivity in picking up these cancers in comparison to
Type II cancers (unpublished data from UKCTOCS).
Type II cancers include high grade serous, high grade endometrioid,
undifferentiated tumours and carcinosarcomas. They are more aggres-
sive and present mostly in late stage [34]. There is mounting descriptive
molecular pathology and experimental evidence that a signiﬁcant pro-
portion of these cancers start as premalignant serous tubal intraepithelial
cancer (STIC) lesions in the ﬁmbrial end of the fallopian tube. STICs are
composed of “secretory cells”, the non-ciliated population of the
endosalpinx and most show strong nuclear staining with antibodies to
p53 as well as an increased proliferation index (MIB-1) compared to
the background tubal epithelium [36,37]. Several studies starting with
the report by Kindelberger et al. [38] have shown that 33–59% of high-
grade serous ovarian and primary peritoneal cancers co-exist with STIC
lesions. In addition, precursor tubal lesions termed “p53 signature”
have been found in one third of all women and are believed to represent
the initial events of serous carcinogenesis—DNA damage of secretory
cells and p53 mutations. These insights open up the prospect of ovarian
cancer screening becoming more akin to cervical cancer screening with
the potential to impact on cancer incidence by intercepting precursors
of pelvic serous cancer. Much depends on discovery of novel detection
methods using exfoliative cytology or imaging to detect these early le-
sions. Unanswered questions include the time interval before early se-
rous cancers metastasise to peritoneal surfaces and whether they are
more curable than advanced malignancies [37].
Inferences frommathematical modelling
On the former front, after decades, progress is being made. Model-
ling using data from published series of occult serous OCs detected at
risk reducing surgery in BRCA1 carriers has yielded some critical in-
sights [39]. It is likely that serous cancers spend, on average, greater
than four years in situ, Stage I or II and possibly a further one year as
Stage III or IV before they present clinically. During this occult period
the cancer is less than 1 cm in size, increasing to just 3 cmwhen it pro-
gresses to an advanced Stage III or IV [40]. There is then explosive
growth with tumours doubling in volume every two and a half months.
This suggests that to achieve 50% sensitivity in detecting tumours before
they advance to Stage III, an annual screen would need to detect tu-
mours of 1.3 cm in diameter.
These ﬁndings suggest that an annual screen could be a viable
screening strategy given the relatively long ‘window of opportunity’
for detection prior to progression to Stage III. However a test that is sen-
sitive and speciﬁc enough would need to detect tumours hundreds of
times smaller than clinically apparent serous cancers. Overcoming the
inherent signal-to-noise problemwill require development of novel ap-
proaches beyond traditional blood biomarkers—discovery of truly
cancer-speciﬁc molecules and use of alternative bio-specimens such as
endocervical swabs, uterine or tubal lavage which would boost signal
to noise by both reducing background from nonmalignant tissues and
avoiding the problem of biomarker dilution inherent in blood-based as-
says. The data also lends further support to the fact that current screen-
ing strategies are more likely to detect low volume high grade serous
(Type II) cancers rather than early stage.
For blood-based biomarkers, Hori and Gambhir undertook mathe-
matical modelling to describe dynamic plasma biomarker kinetics in re-
lation to the growth of a tumour, beginning with a single cancer cell.
They used ovarian carcinoma progression and CA125 shedding in the
average female patient to build themodel. The results suggest that cur-
rent blood assays can only detect tumours 9 to 10 years following the
appearance of the ﬁrst cancer cell at spherical volumes of 25 mm3 or
more [40]. To detect tumour at sizes in the millimetre diameter range
before metastasis, requires extremely high rates of biomarker secretion
by tumour-associated cells, highly accurate assays withmuch lower de-
tection limits than currently in clinical use and essentially zerobackground shedding from healthy cells so that baseline levels in
women without OC are consistently very low.
Cancer speciﬁc biomarkers
Cancer-related genes such as TP53, BRAF and KRAS are frequently
mutated in OC with TP53 mutated in almost all Type II cancers whilst
mutations in BRAF and KRAS are more common in borderline ovarian
tumours and Type I cancers. It has been shown that small amounts of
mutant alleles in cell-free body ﬂuids can be quantiﬁed with unprece-
dented sensitivity by new technologies such as BEAMing [41]. Recently
Forshew and coauthors reported identifyingmutations in TP53 at allelic
frequencies of 2% to 65% in plasma frompatientswith advancedOCwho
had high levels of circulating tumour DNA (ctDNA) using tagged-
amplicon deep sequencing (TAm-Seq). Through several experiments,
the authors were able to show that TAm-Seq is a viable method for se-
quencing large regions of ctDNA. Although this provides a new way to
noninvasively identify gene mutations in blood, TAm-Seq will need to
achieve a more sensitive detection limit (b2% allele frequency) to iden-
tify mutations in the plasma of patients with less advanced cancers.
Nevertheless, once optimised, this low-cost, high-throughput “liquid bi-
opsy” approach may allow detection of small tumours [42]. In the fu-
ture, it would be crucial to assess the TP53 ctDNA signature in healthy
controls.
An equally promising and novel approach was reported by Kinde
et al. who developed a sensitive massively parallel sequencing method
to test formutations in a panel of 12 genes.When applied to 14 liquid cy-
tology cervical samples from women with OC who had mutations, they
were able to identify the expected tumour-speciﬁc mutations. However,
the limitation of the study is that all specimens were from women with
advanced stage disease; the utility of this approach in early stage disease
is yet to be determined. The results demonstrate that in a proportion of
OCs, tumour DNA can be detected in a standard liquid-based cervical cy-
tology specimen obtained during routine pelvic examination [43]. Fur-
ther improvements in the technology for e.g. increasing the number of
potential gene targets could increase the technical sensitivity of the
test whilst improved collection methods such as a small cannula intro-
duced into the endometrial cavity, similar to the Pipelle endometrial bi-
opsy instrument, could theoretically allow a more highly enriched
sample of cells coming from the fallopian tube and ovary.
Autoantibodies warrant further evaluation as OC biomarkers as they
could amplify the signal and improve lead time over CA125.
Longitudinal algorithms
Equally important as the biomarkers themselves, is how results are
interpreted. There is good evidence in the case of biomarkers that are
not cancer speciﬁc such as CA125, single threshold rules used for diagnos-
tic tests are not effective in the context of screening whether in the high
or low risk population. Serial samples are an integral part of screening
and algorithms incorporating change in an individual's marker proﬁle
over time as the cancer evolves have superior sensitivity and speciﬁcity.
Retrospective analysis of PLCO Trial data showed that the CA125 velocity
was a statistically signiﬁcant predictor of OC with average velocity in
those with cancer (19.749 U/ml per month) being more than 500 times
that (0.035 U/ml per month) in women who did not have cancer [44].
Theﬁrst of such time series algorithmswas ROCAdetailed previously,
which was developed in the early 1990s [45]. Following a successful ini-
tial pilot [46], it is now being assessed in screening trials both in the high
[21,23] and low risk populations [14,17]. It has been shown to signiﬁ-
cantly improve screening performance compared to a ﬁxed cut-off for
CA-125 [47]. Preliminary data from UKCTOCS presented at the Helene
Harris Ovarian Cancer meeting in 2010 [48] showed that serial CA125
monitoring using the ROC algorithm can detect OC at tumour sizes too
small to allow detection by transvaginal ultrasound. Between 17th
April 2001 and 30th June 2008, in the multimodal arm of the trial, 147
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gorithm to have risk of OC≥1 in 5 despite two normal or unsatisfactory
transvaginal scans. 15 of the 147 (11.4%) women were found to have
ovarian/tubal/peritoneal malignancies. In the early years of the trial,
there were delays in undertaking surgery due to reluctance on part of
the clinicians to operate in the absence of imaging abnormalities or
symptoms. This suggests that alongside reﬁning such algorithms there
needs to be a change in the clinical paradigm of what an early invasive
epithelial OC looks like.
Other longitudinal algorithms such as theparametric empirical Bayes
(PEB) longitudinal screening algorithm have also been shown to pick up
OC earlier than the single threshold rule in PLCO samples [49]. As panels
of biomarkers complementary to CA125 are assembled, further develop-
ment of such algorithms to take into account the combined proﬁle will
be required to ensure detection of OC at low volumes. The serial samples
available in screening trial biobanks are crucial in developing and vali-
dating such algorithms, whichmay improve the performance of existing
markers.
Real time imaging for cancer screening
Tumour angiogenesis is one of the hallmarks of cancer and is present
early during the development and growth of different solid tumours.
However initial studies using colour ﬂow Doppler to analyse blood
ﬂow to suspicious areas or masses were not found to signiﬁcantly add
to assessment of malignant lesions [50]. Recently, insights into the intri-
cacies of neovascularisation have highlighted a possible oversight that
the microvascular rather than macrovascular pattern may be more
signiﬁcant. Using contrast enhanced transvaginal ultrasound with
microbubbles that are small enough to pass through capillaries, the
kinetics of the bloodﬂowcanbemeasured and analysed to detect abnor-
mal ﬂow found in areas of neovascularisation [51]. Microbubble-
enhanced transvaginal sonography is being used to enhance the evalua-
tion of ovarian masses by early detection of tumour microvascularity.
However in due course it may be part of the screening protocol to iden-
tify OCs in women found to be at increased risk through rising serum
marker proﬁles.
A more powerful imaging tool is targeted contrast-enhanced ultra-
sound imagingwhich has the potential for the detection and quantiﬁca-
tion of tumour angiogenesis at the molecular level. In a recent study,
ultrasonographic microbubbles targeted with one of several antibodies,
anti-integrin, anti-endoglin, or anti-vascular endothelial growth factor
receptor 2 were injected into mice with implanted breast, ovarian, or
pancreatic tumours. As the tumours grew, changes in the relative uptake
of each targeted microbubble were observed, opening up the possibility
of noninvasive in vivo molecular proﬁling of tumour angiogenesis as a
diagnostic tool [52].
Another area being explored is light-induced intrinsic tissue ﬂuo-
rescence or autoﬂuorescence (AF) that may be lost in cancerous/
precancerous epithelial tissue. Assessment of AF enables real time,
high resolution imaging of epithelial tissue and coupled to handheld/
endoscopic devices, it has proven successful in early detection of cervi-
cal, skin, oral and oesophageal cancer. McAlpine et al. have reported
using ex vivo reﬂectance and autoﬂuorescence optical imaging of
tubes removed at surgery to identify STIC lesions with promising levels
of sensitivity (73–100%), speciﬁcity (83–92%), PPV (50–78%) and NPV
(91–100%). Future developments include improving predictive ability
and introducing in vivo real time imaging of the fallopian tube lumen
using endoscopy [53].
Deﬁning the target population
Risk stratiﬁcation improves the effectiveness of screening by
enriching the population for individuals at greatest disease risk. Cur-
rently age and family history of ovarian, breast and colon cancers are
used to deﬁne the low- and high-risk populations, eligible for OCscreening. This is likely to evolve given the signiﬁcant progress made
in the last decade in understanding risk conferred by genetic and epide-
miological factors. There is now good evidence that mutations in the
high-penetrance susceptibility genes (BRCA1, BRCA2 and DNA mis-
match repair genes) only represent an extreme end of a wide spectrum
of OC genetic risk and that several other susceptibility genes exist. The
impact of mutations in these genes is dependent on their minor allele
frequencies and themagnitude of the allelic effect. Mutations in several
moderate risk genes for e.g. RAD51C, RAD51D, and BRIP1 and multiple
low risk (low penetrance) genes could account for the remaining excess
familial risk. In addition, the genome-wide association studies have so
far uncovered eight susceptibility loci for serous epithelial OC [54–58].
These loci harbour low-penetrance alleles with allelic odds ratios of
less than 1.5. As these loci still explain only a small part of the heritable
fraction, further large-scale studies are underway and it is likely that
these numbers will increase [59]. Recently, Pharoah et al. described
the potential value of using multiple, low-penetrance susceptibility al-
leles to reﬁne risk stratiﬁcation in the context of breast cancer screening
strategies [60]. It is conceivable that a similar ‘polygenic’ approach could
be applied to OC. Combining risk related to the genetic variants in these
recent genome-wide association studies and several well-established
environmental risk factors suggests that a multiplicative model is the
best ﬁt [61]. Although the future approaches to screening may include
risk prediction modelling that considers both environmental and
genetic risk factors (both germ line and somatic changes), the models
would be complex and likely need validation in prospective trials. The
implementation of such risk-stratiﬁed screeningwill eventually depend
on a wide array of organisational, ethical, legal and social factors in ad-
dition to usefulness and cost-effectiveness [62].
Conclusion
During the last decade, better understanding of the heterogeneity
of OC and insights into its evolution have clariﬁed the target lesion—
‘primary invasive epithelial ovarian, tubal and peritoneal cancer and
premaligant lesions such as STIC’. Past failures have led to growing num-
bers of biomarker discovery studies using a blinded case control design
nestedwithinpopulation cohorts and focusing on individual OC subtypes.
Modelling has provided insights into the natural history of serous OC and
highlighted the need for highly accurate assays of cancer speciﬁc bio-
markers using novel biospecimens such as cervical cytology that can de-
tect lowvolume tumours. This has translated into early ‘proof of principle’
tests involving deep sequencing technology for mutations in speciﬁc
genes associated with in-situ or low volume disease in tumour DNA iso-
lated from such specimens or more traditional blood samples. Another
key factor that has emerged is the importance of longitudinal algorithms
in improving biomarker performance in the context of screening.
There was no mortality beneﬁt of ovarian cancer screening in the
PLCO trial. However the longitudinal algorithm ROCA used in UKCTOCS
has shown encouraging performance characteristics both on prevalence
and incidence screening. Preliminary data from the trial suggests that
CA125 risewithin normal range can be detected by the ROCAwell before
any abnormalities are detected on transvaginal imaging. Whether this
converts into amortality impactwill only be known in 2015.Meanwhile
major efforts are underway to improve OC risk stratiﬁcation and identify
populations at greatest risk of disease.
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